NPI 1306886916: Open Payments
NPI 1306886916. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,196 in 82 payments from 12 companies in 2025. Trend: 2023 $1,456 · 2024 $2,364 · 2025 $1,196
Food & beverage: $1,196
| Company | Payments | Amount |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 32 | $461 |
| Indivior Inc. | 30 | $342 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $137 |
| PFIZER INC. | 5 | $79 |
| Saluda Medical Americas, Inc. | 2 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Virtus Pharmaceuticals LLC | 1 | $23 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Braeburn Inc. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
Products named: Belbuca, SUBLOCADE, RELISTOR, NURTEC ODT, Evoke, TRINTELLIX, LEVORPHANOL TARTRATE, Auvelity.
